Tirzepatide for weight loss: separating real data from TikTok hype

What did @anastasiaartemiou actually say?

She's on a 10mg tirzepatide dose, has lost 47 pounds total (20 on semaglutide, the rest on tirzepatide), and is self-injecting at home. She says "tirzepatide has less side effects than semaglutide," specifically calling out sulfur burps as something she experienced on semaglutide but not tirzepatide. She also describes classic end-of-dose hunger return, food aversion mid-cycle, and mentions needing to stop tirzepatide about a month before an upcoming surgical procedure. She's planning to stay on a "maintenance dose" long-term.

She's speaking from lived experience, which has real value. But several of her offhand claims deserve a closer look, because 11,600 people are watching this and some of them are making medication decisions based on what she says.

Does the science back this up?

On the core claim that tirzepatide produces fewer GI side effects than semaglutide, the evidence is genuinely mixed. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed nausea rates of 25-30% with tirzepatide at higher doses, which is not trivially low. Head-to-head data is limited.

The SURPASS-2 trial (Frías et al., 2021, NEJM) compared tirzepatide directly to semaglutide 1mg and found tirzepatide produced greater weight loss but similar or slightly lower nausea rates at comparable doses. A 2023 network meta-analysis by Shi et al. in Diabetes, Obesity and Metabolism found tirzepatide's GI side effect profile was broadly comparable to semaglutide, not dramatically better. Individual variation is large. Her personal experience is plausible, but framing tirzepatide as categorically easier on the gut is an oversimplification.

The "end-of-week hunger return" she describes is pharmacologically coherent. Tirzepatide has a half-life of roughly five days, so appetite suppression does taper before the next weekly injection.

What did they get wrong (or right)?

Credit where it's due: her description of food aversion and the end-of-dose hunger rebound is accurate and well-documented in patient-reported outcomes. She's also right that pre-surgical discontinuation is standard practice. Most surgical teams do request stopping GLP-1 agonists before general anesthesia, primarily due to gastroparesis risk and aspiration concerns. The American Society of Anesthesiologists issued guidance in 2023 recommending stopping weekly GLP-1 agents at least one week prior, though many surgeons request longer windows.

Where she goes wrong: comparing her 10mg tirzepatide dose experience to her semaglutide experience and drawing a general conclusion about which drug is "easier" is not a valid comparison. She was on different doses, at different stages of treatment, with a different body composition. Dose, timing, and individual GI sensitivity all affect side effect burden. Viewers shouldn't expect tirzepatide to be a gentler option just because it was for her.

The plan to message her provider about dose escalation is appropriate. That is how the titration process is supposed to work.

What should you actually know?

Tirzepatide is a dual GIP and GLP-1 receptor agonist. Semaglutide acts only on GLP-1 receptors. They are different molecules with different mechanisms, and the assumption that one is uniformly gentler than the other is not well-supported in the literature.

A few things anyone watching this should keep in mind:

• Self-injection technique matters. Injection site, needle angle, and skin temperature all affect discomfort. Her comment that clinic injections hurt less is consistent with trained administration technique.
• Stopping GLP-1 therapy before surgery is a real clinical concern. The aspiration risk from delayed gastric emptying is serious enough that most anesthesiologists now ask about these medications explicitly. One week is a common minimum, but her surgeon may require longer.
• "Maintenance dosing" is a real concept in GLP-1 therapy, but the appropriate dose for maintenance is not the same for everyone. This is a conversation to have with a prescriber, not something to decide based on how you feel at 132 pounds.
• Weight regain after stopping GLP-1 agents is well-documented. The STEP 4 trial (Rubino et al., 2021, JAMA) showed participants regained two-thirds of lost weight within a year of stopping semaglutide.

The bottom line

This creator is sharing her real experience, and a lot of it is accurate. But her framing of tirzepatide as having fewer side effects than semaglutide is presented as fact when it's really her personal comparison under different conditions. Viewers who switch medications expecting a smoother ride based on her experience may be surprised. Medication response is individual. Talk to a licensed prescriber before drawing conclusions from someone else's injection video.